Studying the Elimination of Anti-Rejection Medications

Kidney transplant recipients deal with taking anti-rejection meds for life. Talaris is developing an alternative to immunosuppression. Nancy Krieger, MD, Talaris Therapeutics Chief Medical Officer, explains how this new treatment will work and how it differs from what is currently prescribed. She also talks about how you can learn more about the clinical trials that are available.

 

Learn more about the Talaris Therapeutics Freedom-1 

You can also listen to and download the podcast with these apps:

Apple Podcasts

Google Podcasts 

iHeart Radio

Amazon Podcasts

Hosted By Lori Hartwell

Lori Hartwell is the Founder & President of Renal Support Network (RSN) and the host of KidneyTalk®, a radio podcast show. Lori was diagnosed with kidney disease at the age of two. In 1993 she founded RSN to instill “health, happiness and hope” into the lives of those affected by chronic kidney disease. Lori is also the author of the inspirational book Chronically Happy: Joyful Living in Spite of Chronic Illness and is a four-time kidney transplant recipient.

Web ID 3071